In order to discover an anti-CRISPR protein that would work against the type of CRISPR-Cas9 system most labs now use, which depends on a protein called SpyCas9 as its targeted DNA clippers, researchers from University of California, San Francisco (UCSF) in the US came up with a clever trick.
They reasoned that they should be able to identify bacteria with inactivated CRISPR systems by looking for evidence of so-called "self-targeting" - bacterial strains where some virus had successfully gotten through the Cas9 blockade and inserted its genes into the bacterial genome.
CRISPR-Cas9 evolved in bacteria as an immune system to protect against viral infections.
However, in the past decade it has excited both researchers and the general public as a general-use gene editing system, enabling scientists to quickly and efficiently modify genetic information and tweak gene activity in virtually any organism.
Many hope CRISPR will speed efforts to directly treat genetic disorders, among many other applications, but for the most part the technology has not yet proven quite precise enough, making occasional unintended edits along with the intended ones.
The newly discovered anti-CRISPR proteins - which are the first to work against the type of CRISPR-Cas9 system most commonly used by laboratories and the burgeoning gene editing industry - could help resolve both problems, enabling more precise control in CRISPR applications but also providing a fail-safe to quickly block any potentially harmful uses of the technology.
To find such a switch, researchers turned to the same billion-year arms race between viruses and bacteria that produced the CRISPR system itself.
Using a bioinformatics approach the team examined nearly 300 strains of Listeria, a bacterial genus famous for its role in food-borne illness and found that three per cent of strains exhibited "self-targeting".
Further investigation isolated four distinct anti-CRISPR proteins that proved capable of blocking the activity of the Listeria Cas9 protein, which is very similar to SpyCas9.
The study was published in the journal Cell.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
